3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma, Malignant
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Vascular Endothelial Growth Factor A
×
Thoracic
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled